Nyxoah (NYXH NASDAQ) stock market data APIs
$1.489
0.01(0.7%)
as of September 18, 2026
Try our APIs with
free plan!
Nyxoah Financial Data Overview
Price chart is built with
Anychart
Nyxoah SA, a medical technology company, focuses on the development and commercialization of solutions to treat obstructive sleep apnea. Its lead solution is the Genio system, a hypoglossal neurostimulations therapy for obstructive sleep apnea. The company was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.
Prev. Close
1.489
Open
1.4992
High
1.5054
Low
1.4797
52 wk Range
1.26-6.8745
Market Cap
151 M
Shares Outstanding
102 M
Revenue
21 663 K
EPS
-0.67
Beta
0.963
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Nyxoah data using free add-ons & libraries
Get Nyxoah Fundamental Data
Nyxoah Fundamental data includes:
- Net Revenue: 21 663 K
- EBITDA: -82 744 000
- Earnings Per Share: -2
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-08-05
- EPS/Forecast: -0.47
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Nyxoah News
New
Nyxoah (NYXH) Begins BREATHE Study. Can Real-World Evidence Drive Genio Adoption?
Nyxoah SA (NASDAQ:NYXH) announced the first patient implantation in BREATHE on September 7. The prospective, single-arm U.S. post-approval study will evaluate Genio hypoglossal-nerve stimulation in ad...
Nyxoah Stock Down Despite First Genio Implant in U.S. BREATHE Trial
Nyxoah NYXH recently initiated its U.S. post-approval BREATHE study with the first patient implanted using the Genio system, marking an important step in expanding clinical evidence for its obstructiv...
Nyxoah Announces First Patient Implanted in BREATHE, the U.S. Post-Approval Study of the Genio® System
Nyxoah Nyxoah Announces First Patient Implanted in BREATHE, the U.S. Post-Approval Study of the Genio® System BREATHE is scheduled to implant up to 229 patients at up to 25 U.S. centers, followed f...
Nyxoah Shares Jump After Genio Meets Primary Endpoints in CCC Patient Study
Nyxoah SA (NYXH) shares jumped 15% in Wednesday trading after it said its ACCCESS US pivotal study m PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscri...
Get Nyxoah fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
Best Offer
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
